Improved overall survival and mortality in head and neck cancer with adjuvant concurrent chemoradiotherapy in national databases

Head Neck. 2016 Feb;38(2):208-15. doi: 10.1002/hed.23869. Epub 2015 May 25.

Abstract

Background: Many studies have demonstrated the advantage of postoperative concurrent chemoradiotherapy (CRT) over radiotherapy (RT) alone in locoregional control, but few have examined overall survival with respect to national databases.

Methods: The literature was searched for eligible randomized controlled trials. The Surveillance, Epidemiology, and End Results (SEER) Database and National Cancer Data Base (NCDB) were searched for 5-year overall survival data.

Results: Twenty-eight studies were examined and demonstrated 44% greater locoregional control (relative risk [RR] = 0.56; 95% confidence interval [CI] = 0.46-0.68) and 12% overall survival benefit (RR = 0.88; 95% CI = 0.81-0.98) with postoperative adjuvant CRT compared to adjuvant RT. Overall SEER survival was 45.0% in 1973, rising to 53.2% in 2005. The NCDB documents a similar increase in overall survival from 45.5% in 1994 to 53.4% in 2005.

Conclusion: The literature shows mortality benefit of adjuvant CRT in patients with advanced head and neck cancer, reflected in SEER and NCDB.

Keywords: adjuvant chemoradiotherapy; concurrent chemoradiotherapy; head and neck cancer; overall survival; reduced mortality.

Publication types

  • Review

MeSH terms

  • Chemoradiotherapy, Adjuvant*
  • Databases, Factual
  • Head and Neck Neoplasms / mortality*
  • Head and Neck Neoplasms / therapy*
  • Humans
  • Randomized Controlled Trials as Topic
  • SEER Program
  • Survival Analysis
  • United States / epidemiology